Search

Your search keyword '"Furman, R"' showing total 10 results
Start Over Author "Furman, R" Journal leukemia
10 results on '"Furman, R"'

2. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

Author

Brown, J R, Hillmen, P, OʼBrien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, and Byrd, J C

Published
2018
Full Text
View/download PDF

5. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

Author

Brown, J R, primary, Hillmen, P, additional, O’Brien, S, additional, Barrientos, J C, additional, Reddy, N M, additional, Coutre, S E, additional, Tam, C S, additional, Mulligan, S P, additional, Jaeger, U, additional, Barr, P M, additional, Furman, R R, additional, Kipps, T J, additional, Cymbalista, F, additional, Thornton, P, additional, Caligaris-Cappio, F, additional, Delgado, J, additional, Montillo, M, additional, DeVos, S, additional, Moreno, C, additional, Pagel, J M, additional, Munir, T, additional, Burger, J A, additional, Chung, D, additional, Lin, J, additional, Gau, L, additional, Chang, B, additional, Cole, G, additional, Hsu, E, additional, James, D F, additional, and Byrd, J C, additional

Published
2017
Full Text
View/download PDF

6. Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22

Author

Arruga, F, primary, Gizdic, B, additional, Bologna, C, additional, Cignetto, S, additional, Buonincontri, R, additional, Serra, S, additional, Vaisitti, T, additional, Gizzi, K, additional, Vitale, N, additional, Garaffo, G, additional, Mereu, E, additional, Diop, F, additional, Neri, F, additional, Incarnato, D, additional, Coscia, M, additional, Allan, J, additional, Piva, R, additional, Oliviero, S, additional, Furman, R R, additional, Rossi, D, additional, Gaidano, G, additional, and Deaglio, S, additional

Published
2016
Full Text
View/download PDF

8. Mutations in NOTCH1PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22

Author

Arruga, F, Gizdic, B, Bologna, C, Cignetto, S, Buonincontri, R, Serra, S, Vaisitti, T, Gizzi, K, Vitale, N, Garaffo, G, Mereu, E, Diop, F, Neri, F, Incarnato, D, Coscia, M, Allan, J, Piva, R, Oliviero, S, Furman, R R, Rossi, D, Gaidano, G, and Deaglio, S

Abstract

Even if NOTCH1is commonly mutated in chronic lymphocytic leukemia (CLL), its functional impact in the disease remains unclear. Using CRISPR/Cas9-generated Mec-1 cell line models, we show that NOTCH1 regulates growth and homing of CLL cells by dictating expression levels of the tumor suppressor gene DUSP22. Specifically, NOTCH1 affects the methylation of DUSP22promoter by modulating a nuclear complex, which tunes the activity of DNA methyltransferase 3A (DNMT3A). These effects are enhanced by PEST-domain mutations, which stabilize the molecule and prolong signaling. CLL patients with a NOTCH1-mutated clone showed low levels of DUSP22 and active chemotaxis to CCL19. Lastly, in xenograft models, NOTCH1-mutated cells displayed a unique homing behavior, localizing preferentially to the spleen and brain. These findings connect NOTCH1, DUSP22, and CCL19-driven chemotaxis within a single functional network, suggesting that modulation of the homing process may provide a relevant contribution to the unfavorable prognosis associated with NOTCH1mutations in CLL.

Published
2017
Full Text
View/download PDF

9. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies

Author

Raquel Izumi, Simon Rule, Jeff P. Sharman, Richard R. Furman, John M. Pagel, Susan O'Brien, Priti Patel, John C. Byrd, Beth Christian, Tamara Lezhava, Peter Hillmen, Marshall Baek, Ahmed Hamdy, Jennifer R. Brown, Clare Sun, Martin J.S. Dyer, Michael Wang, Roger G. Owen, Deborah M. Stephens, Nataliya Chernyukhin, Wojciech Jurczak, Paolo Ghia, Matthew Streetly, Furman, R. R., Byrd, J. C., Owen, R. G., O'Brien, S. M., Brown, J. R., Hillmen, P., Stephens, D. M., Chernyukhin, N., Lezhava, T., Hamdy, A. M., Izumi, R., Patel, P., Baek, M., Christian, B., Dyer, M. J. S., Streetly, M. J., Sun, C., Rule, S., Wang, M., Ghia, P., Jurczak, W., Pagel, J. M., and Sharman, J. P.

Subjects
0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Nausea, Anemia, Antineoplastic Agents, Neutropenia, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Adverse effect, Aged, Retrospective Studies, Aged, 80 and over, Clinical Trials as Topic, business.industry, Hematology, Middle Aged, medicine.disease, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, United States, Discontinuation, Survival Rate, Pneumonia, 030104 developmental biology, Upper respiratory tract infection, Oncology, Tolerability, 030220 oncology & carcinogenesis, Pyrazines, Benzamides, Female, medicine.symptom, business, Follow-Up Studies
Abstract

Bruton tyrosine kinase (BTK) inhibition is an effective therapy for many B-cell malignancies. Acalabrutinib is a next-generation, potent, highly selective, covalent BTK inhibitor. To characterize acalabrutinib tolerability, we pooled safety data from 1040 patients with mature B-cell malignancies treated with acalabrutinib monotherapy in nine clinical studies (treatment-naive: n = 366 [35%], relapsed/refractory: n = 674 [65%]; median [range] age: 67 [32–90] years; median [range] prior treatments: 1 [0–13]; median [range] duration of exposure: 24.6 [0.0–58.5] months). The most common adverse events (AEs) were headache (38%), diarrhea (37%), upper respiratory tract infection (22%), contusion (22%), nausea (22%), fatigue (21%), and cough (21%). Serious AEs (SAEs) occurred in 39% of patients; pneumonia (6%) was the only SAE that occurred in ≥2%. Deaths due to AEs occurred in 52 patients (5%); pneumonia (n = 8) was the only fatal AE to occur in ≥3 patients. AEs led to treatment discontinuation in 9%. Rates for the AEs of interest (all grades) included infections (67%), hemorrhages (46%), neutropenia (16%), anemia (14%), second primary malignancies (12%), thrombocytopenia (9%), hypertension (8%), and atrial fibrillation (4%). This pooled analysis confirmed acalabrutinib’s tolerability and identified no newly emerging late toxicities, supporting acalabrutinib as a long-term treatment for patients with mature B-cell malignancies.

Published
2020

10. Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.

Author

Brown JR, Zelenetz A, Furman R, Lamanna N, Mato A, Montillo M, O'Brien S, Dubowy R, Gu L, Munugalavadla V, Robak T, and Hillmen P

Subjects
Humans, Risk Factors, Antineoplastic Agents therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Purines therapeutic use, Quinazolinones therapeutic use, Transaminases metabolism
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results